NCT04632680View on ClinicalTrials.gov

ECG-I Targeted Ablation for Persistent AF

NACompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Atrial Fibrillation
Interventions
DEVICE

PVI followed by targeting of drivers

Patients will undergo intraprocedural ECG-I mapping. The pulmonary veins will be isolated followed by targeting of drivers aiming to terminate AF.

Trial Locations (1)

EC1A 7BE

Barts Heart Centre, London

All Listed Sponsors
lead

Barts & The London NHS Trust

OTHER

NCT04632680 - ECG-I Targeted Ablation for Persistent AF | Biotech Hunter | Biotech Hunter